Antiphospholipid syndrome is defined by the combination of thrombotic events and/or obstetric morbidity in patients who have tested positive persistently for antiphospholipid antibodies. With good treatment, approximately 70% of pregnant women with antiphospholipid syndrome will deliver a viable live infant. However, current management does not prevent all maternal, fetal, and neonatal complications of antiphospholipid syndrome.
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies
SCIASCIA, SavinoFirst
;
2016-01-01
Abstract
Antiphospholipid syndrome is defined by the combination of thrombotic events and/or obstetric morbidity in patients who have tested positive persistently for antiphospholipid antibodies. With good treatment, approximately 70% of pregnant women with antiphospholipid syndrome will deliver a viable live infant. However, current management does not prevent all maternal, fetal, and neonatal complications of antiphospholipid syndrome.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
HCQ V 8.docx
Accesso riservato
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
104.23 kB
Formato
Adobe PDF
|
104.23 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
|
25_26429521_4aperto.pdf
Open Access dal 02/10/2016
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
406.66 kB
Formato
Adobe PDF
|
406.66 kB | Adobe PDF | Visualizza/Apri |
|
Sciascia_1_213386_The impact.pdf
Accesso riservato
Tipo di file:
PDF EDITORIALE
Dimensione
180.18 kB
Formato
Adobe PDF
|
180.18 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
